
Elekta launches AI-powered, adaptive CT-Linac for next level cancer care

New radiation therapy system, Elekta Evo, features next generation image quality and online adaptive capabilities for cancer treatments

STOCKHOLM – Elekta (EKTA-B.ST) today announced the launch of its latest linear accelerator (linac), Evo*, a CT-Linac with new high-definition AI enhanced imaging, capable of delivering offline and online adaptive radiation therapy as well as improved standard image-guided radiation therapy treatments. This highly versatile CT-Linac will enable clinicians to choose the most suitable radiation therapy technique for each individual patient.

Evo was introduced at Europe's largest industry exhibition in radiation oncology, the Annual Congress of the European Society for Radiotherapy and Oncology (ESTRO 2024) in Glasgow, Scotland.

Gustaf Salford, Elekta's CEO, said: "We are very excited to introduce an adaptive CT-Linac that is designed from our commitment to delivering groundbreaking image guided radiation therapy technology. Elekta Evo truly brings hope for more precise, personalized and effective care, which will benefit all those who deal with cancer. Once again, Elekta demonstrates dedication to accelerate innovation in cancer care."

Adaptive radiotherapy can reduce uncertainties and therefore reduce potential harm to organs at risk. The overall aim is better targeting, reduced side effects, and improved quality of life for patients. At the heart of Evo lies its powerful AI capabilities and anatomy-specific algorithms. The system's high-definition imaging, Iris™, will allow clinicians to precisely visualize target areas, as well as increase automation and speed.

To optimize the treatment planning, including offline and online planning, Elekta introduced a new extension of Elekta ONE in its comprehensive software portfolio: Elekta ONE Planning, [powered by MIM](#). Elekta ONE Planning, brings distributed treatment planning, faster dose calculation and AI-driven automation in contouring and dose planning. It supports both Elekta and non-Elekta devices, including proton therapy, making it the most competitive solution in the market.

Maurits Wolleswinkel, Elekta's President Linac and Software Solutions, said: "Evo is an incredibly versatile linac that – in the era of increasingly stretched resources – will give our customers the freedom to adopt new technologies at their own pace. With the recently announced treatment planning enhancements to our Elekta ONE software suite, we now have a comprehensive offering for increased personalization as well as versatility that can take radiation therapy to the next level."

For more information on Evo, visit elekta.com/adapt-at-your-rhythm or stop by Elekta booth 440, May 3-7 at ESTRO 2024.

**Elekta Evo requires CE mark certification and is not available in all markets.*

###



For further information, please contact:

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com

Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations

Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com

Time zone: ET: Eastern Time

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow [@Elekta](https://twitter.com/Elekta) on "X", formerly known as Twitter.